
Celcuity (CELC) Stock Forecast & Price Target
Celcuity (CELC) Analyst Ratings
Bulls say
Celcuity Inc. has demonstrated a substantial stock price appreciation of approximately 608% year-to-date, significantly outperforming key market indices which include a 28.7% gain for the Nasdaq Biotechnology Index and a 14.5% increase for the S&P 500. The company's optimistic outlook is further reinforced by increased sales estimates for its lead candidate, gedatolisib, which have risen to $70 million, $462 million, and $827 million for 2023, 2024, and 2025 respectively, reflecting expedited regulatory reviews and enhanced market share in both PIK3CA wild-type and mutant patient populations. The upcoming topline data from the VIKTORIA-1 trial is expected to yield a favorable risk/reward profile, bolstered by positive clinical validation supporting gedatolisib's efficacy across varying patient mutations, thereby strengthening investor confidence in the stock's potential.
Bears say
Celcuity Inc's financial outlook is concerning due to a projected $45 million total expenditure, which includes a $35 million decrease in R&D spending, indicating potential issues in their development pipeline. The company's cautious stance is attributed to the risks associated with upcoming regulatory decisions and their ability to compete against larger pharmaceutical companies with established market presence, particularly if FDA approval delays occur or if pricing pressures emerge from payors. Furthermore, the current valuation of $4.3 billion may not accurately reflect the potential for adoption or revenue per patient, leading to fears of a stock price reevaluation if anticipated financial metrics do not materialize.
This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares